Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy.
To investigate the involvement of vitronectin, the terminal complement complex (C5b-9), and the vitronectin receptor in the pathogenesis of membranous nephropathy, the immunohistochemical localization of these antigens in the kidney was determined using the immunoperoxidase method and monoclonal antibodies: antivitronectin, anti-SC5b-9 (neoantigen), and antivitronectin receptor (specific for alpha v beta 3 and alpha v). The subjects were 6 patients with membranous nephropathy, and the controls were 2 patients with minimal-change nephrotic syndrome. In membranous nephropathy, vitronectin was localized in subepithelial deposits and in epithelial cell foot processes and was intensely positive in the foot processes adjacent to subepithelial deposits. C5b-9 showed a similar pattern of localization to vitronectin. Both alpha v beta 3 and alpha v were localized in the basal portions of the foot processes of visceral epithelial cells as well as along the borders of these cells adjacent to the urinary space. Deposition at the former site was heavier than at the latter, and localization was especially prominent adjacent to the subepithelial deposits. In addition, alpha v was localized around and within some of the electron-lucent subepithelial deposits in the basement membrane. In contrast, the deposition of vitronectin, C5b-9, alpha v beta 3, and alpha v was always less intense in minimal-change nephrotic syndrome than in membranous nephropathy. Vitronectin and C5b-9 were localized to small parts of mesangium and glomerular basement membrane, while alpha v beta 3 and alpha v deposits showed no difference in intensity between the basal portions of the foot processes and the urinary border of the visceral epithelial cells. Thus, membranous nephropathy featured increased localization of vitronectin, C5b-9, and vitronectin receptors both within and around the subepithelial deposits, suggesting that the mechanism of immune complex disposal via the vitronectin receptor and the vitronectin-C5b-9 complex, associated with complement activation due to subepithelial immune complex formation, may also be active.
Ogawa
T
T
2nd Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Yorioka
N
N
Yamakido
M
M
D000328:Adult; D000368:Aged; D001706:Biopsy; D015938:Complement Membrane Attack Complex / Q000032:analysis*; D016326:Extracellular Matrix Proteins / Q000032:analysis*; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D016023:Integrins / Q000032:analysis*; D007668:Kidney / Q000737:chemistry / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D009402:Nephrosis, Lipoid / Q000276:immunology / Q000473:pathology; D016024:Receptors, Cytoadhesin / Q000032:analysis*; D019030:Receptors, Vitronectin; D019096:Vitronectin
D015938:Complement Membrane Attack Complex; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D016023:Integrins; D016024:Receptors, Cytoadhesin; D019030:Receptors, Vitronectin; D019096:Vitronectin